Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTC:AAWH OTCMKTS:CRLBF NASDAQ:ORKA NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.84+7.7%$0.47$0.26▼$1.02$171.73M1.04164,158 shs1.05 million shsCRLBFCresco Labs$1.51+1.8%$0.77$0.43▼$1.80$726.71M1.422.05 million shs1.25 million shsORKAOruka Therapeutics$14.80-3.1%$13.85$5.49▼$33.00$571.87M-0.35148,626 shs89,825 shsXNCRXencor$8.13+1.0%$8.29$6.92▼$27.24$574.15M0.89749,722 shs769,384 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness+7.69%+18.11%+79.68%+162.42%-9.58%CRLBFCresco Labs+2.52%+21.97%+134.95%+143.85%+1.14%ORKAOruka Therapeutics-3.08%-4.15%+7.32%+34.06%+1,479,999,900.00%XNCRXencor+0.99%-3.33%-6.87%+5.58%-52.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAAWHAscend Wellness0.8982 of 5 stars0.05.00.00.00.61.70.6CRLBFCresco Labs0.6359 of 5 stars0.03.00.00.03.30.00.6ORKAOruka Therapeutics2.5971 of 5 stars3.60.00.00.02.22.50.6XNCRXencor3.6691 of 5 stars3.40.00.03.92.80.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAWHAscend Wellness 1.00SellN/AN/ACRLBFCresco Labs 3.00BuyN/AN/AORKAOruka Therapeutics 3.20Buy$40.38172.80% UpsideXNCRXencor 2.75Moderate Buy$23.71191.69% UpsideCurrent Analyst Ratings BreakdownLatest AAWH, ORKA, XNCR, and CRLBF Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025XNCRXencorRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $15.008/18/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.008/12/2025AAWHAscend WellnessZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong Sell8/12/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.008/7/2025XNCRXencorWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$33.00 ➝ $27.008/7/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$31.00 ➝ $26.007/23/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.007/21/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.006/3/2025CRLBFCresco LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy(Data available from 8/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAWHAscend Wellness$518.59M0.33$0.13 per share6.64$0.69 per share1.22CRLBFCresco Labs$724.34M1.02N/AN/A$0.74 per share2.04ORKAOruka TherapeuticsN/AN/AN/AN/A$9.10 per shareN/AXNCRXencor$110.49M5.25N/AN/A$8.70 per share0.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAWHAscend Wellness-$48.21M-$0.42N/AN/AN/A-15.47%-72.18%-9.55%N/ACRLBFCresco Labs-$74.44M-$0.13N/AN/AN/A-6.67%-11.77%-3.22%11/14/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$2.81N/AN/AN/AN/A-26.26%-24.16%11/12/2025 (Estimated)XNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest AAWH, ORKA, XNCR, and CRLBF EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q1 2025ORKAOruka Therapeutics-$0.48-$0.46+$0.02-$0.46N/AN/A8/7/2025Q2 2025CRLBFCresco Labs-$0.04-$0.05-$0.01-$0.05$162.00 million$163.62 million8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 million5/30/2025Q1 2025CRLBFCresco Labs-$0.03-$0.04-$0.01-$0.04$164.37 million$165.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAWHAscend WellnessN/AN/AN/AN/AN/ACRLBFCresco LabsN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAWHAscend Wellness2.611.470.80CRLBFCresco Labs1.333.102.22ORKAOruka TherapeuticsN/A27.4227.42XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAWHAscend Wellness17.31%CRLBFCresco Labs0.05%ORKAOruka Therapeutics56.44%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipAAWHAscend Wellness22.38%CRLBFCresco LabsN/AORKAOruka Therapeutics24.69%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAWHAscend Wellness2,300204.44 million166.44 millionNot OptionableCRLBFCresco Labs2,900491.02 millionN/ANot OptionableORKAOruka TherapeuticsN/A37.45 million28.20 millionN/AXNCRXencor28071.32 million67.93 millionOptionableAAWH, ORKA, XNCR, and CRLBF HeadlinesRecent News About These CompaniesPrice T Rowe Associates Inc. MD Decreases Position in Xencor, Inc. $XNCRAugust 30 at 4:22 AM | marketbeat.comInvesco Ltd. Raises Holdings in Xencor, Inc. $XNCRAugust 29 at 3:23 AM | marketbeat.comXencor to Participate at Upcoming Investor ConferencesAugust 27 at 4:01 PM | businesswire.comVanguard Group Inc. Trims Stake in Xencor, Inc. $XNCRAugust 26, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Receives $23.71 Consensus Target Price from BrokeragesAugust 25, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by AnalystsAugust 24, 2025 | marketbeat.comAberdeen Group plc Grows Holdings in Xencor, Inc. $XNCRAugust 23, 2025 | marketbeat.comRoyal Bank Of Canada Lowers Xencor (NASDAQ:XNCR) Price Target to $15.00August 23, 2025 | americanbankingnews.comXencor, Inc. $XNCR Stock Holdings Lifted by Public Sector Pension Investment BoardAugust 22, 2025 | marketbeat.comXencor price target lowered to $15 from $32 at RBC CapitalAugust 21, 2025 | msn.comQ3 Earnings Estimate for Xencor Issued By Leerink PartnrsAugust 11, 2025 | marketbeat.comWedbush Estimates Xencor's Q3 Earnings (NASDAQ:XNCR)August 11, 2025 | marketbeat.comWilliam Blair Analysts Boost Earnings Estimates for XencorAugust 11, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.37 EPSAugust 10, 2025 | marketbeat.comXencor (XNCR) Receives a Buy from Leerink PartnersAugust 9, 2025 | theglobeandmail.comXencor, Inc. (NASDAQ:XNCR) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 9, 2025 | finance.yahoo.comXencor (XNCR) Q2 Revenue Jumps 82%August 9, 2025 | theglobeandmail.comXencor (NASDAQ:XNCR) Hits New 12-Month Low on Analyst DowngradeAugust 8, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Given New $27.00 Price Target at Wells Fargo & CompanyAugust 8, 2025 | marketbeat.comWedbush Lowers Xencor (NASDAQ:XNCR) Price Target to $26.00August 8, 2025 | marketbeat.comXencor price target lowered to $26 from $31 at WedbushAugust 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAAWH, ORKA, XNCR, and CRLBF Company DescriptionsAscend Wellness OTC:AAWH$0.84 +0.06 (+7.69%) As of 08/29/2025 03:59 PM EasternAscend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.Cresco Labs OTCMKTS:CRLBF$1.51 +0.03 (+1.82%) As of 08/29/2025 03:59 PM EasternCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.Oruka Therapeutics NASDAQ:ORKA$14.80 -0.47 (-3.08%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$14.80 0.00 (0.00%) As of 08/29/2025 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Xencor NASDAQ:XNCR$8.13 +0.08 (+0.99%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.13 0.00 (0.00%) As of 08/29/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
